Literature DB >> 8236506

Intestinal-type adenocarcinoma of the sinonasal tract: a clinicopathologic study of 18 cases.

C Urso1, M B Ninu, A Franchi, M Paglierani, R Bondi.   

Abstract

BACKGROUND: Intestinal-type adenocarcinoma (ITAC) of the nose and paranasal sinuses is a relatively rare tumor. It commonly affects subjects exposed to wood or leather dust.
METHODS: The authors present the clinicopathologic findings of 18 cases of sinonasal ITACs and review the proposed histologic classifications.
RESULTS: All patients, except one, were males; mean age was 60 years (range, 41-79); in 9 cases an occupational exposure to wood or leather dust was found. Common presenting symptoms were epistaxis, nasal obstruction and rhinorrhea. Histologically, tumors were divided into four groups: well-differentiated (G1) ITACs = 3 cases; moderately differentiated (G2) ITACs = 8 cases; poorly differentiated (G3) ITACs = 2 cases; mucinous (M) ITACs = 5 cases. Immunocytochemically, 16/17 cases were positive for carcinoembryonal antigen, 1/17 for somatostatin, and 0/16 cases for gastrin.
CONCLUSIONS: Sinonasal ITACs are aggressive tumors, often diagnosed in a relatively advanced stage. Owing the close similarity of the microscopic aspects, a histologic classification of ITACs analogous to that of colonic adenocarcinomas is proposed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8236506     DOI: 10.1177/030089169307900310

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  CDX-2, cytokeratin 7 and cytokeratin 20 immunohistochemical expression in the differential diagnosis of primary adenocarcinomas of the sinonasal tract.

Authors:  A Franchi; D Massi; A Palomba; M Biancalani; M Santucci
Journal:  Virchows Arch       Date:  2004-06-03       Impact factor: 4.064

2.  Among sinonasal tumors, CDX-2 immunoexpression is not restricted to intestinal-type adenocarcinomas.

Authors:  Matthew P Tilson; Gary L Gallia; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2013-07-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.